As India’s contract manufacturing and development organization (CDMO) is set to double in the next decade, Anthem Biosciences ...

Anthem Biosciences, an India-based CDMO, submitted a filing (PDF) at the end of 2024 to announce its plans for a 33.95 ...

(Reuters) -Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion ... are among investors who will sell shares in the IPO. The company will not sell any shares and it did not ...

Contract research company Anthem Biosciences has filed for a Rs 3,395 ... The selling shareholders will be entitled to the proceeds from the IPO and the company will not receive any proceeds ...

India-based drug manufacturer Anthem Biosciences has its sights on going public with an IPO that could raise 34 billion rupees ($397 million).

Indian contract drugmaker Anthem Biosciences filed for a ₹3,395 crore ... are among the investors who will sell shares in the IPO. The company will not sell shares and did not give any other ...

Anthem Biosciences on Tuesday (December 31 ... The proposed initial public offer (IPO) is entirely an offer for sale (OFS) worth ₹3,395 crore by promoters, investors and other selling ...

The Bengaluru-based pharma company is run by Ajay Bhardwaj, a former Biocon executive, who is the founder, CEO and Managing Director at Anthem Biosciences. The company was incorporated in 2006.

Dec 31 (Reuters) - Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion ... are among investors who will sell shares in the IPO. The company will not sell any shares and it ...

Anthem Biosciences Limited, an innovation-driven and technology ... SEBI to raise funds through an initial public offering (IPO). Ajay Bhardwajm, chairman, MD & CEO, Ishaan Bhardwaj, vice president, ...